CP101 JAK Who? Update on the WHO Classification and Clinical Management of Myeloproliferative Neoplasms
2:00–4:00 pm
2.5 CME/SAM CREDITS
The 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues included major changes in the classification of myeloproliferative neoplasms (MPNs). Recent discovery of abnormalities involving genes such as JAK2, MPL, and PDGFRA/B, and the recognition of the importance of bone marrow histology have driven the adoption of a semimolecular classification scheme. It is now recognized that the majority of MPNs are related to the constitutive activation of tyrosine kinases, resulting in enhanced cell signaling and a proliferative phenotype. These aberrant protein tyrosine kinases also provide opportunities for novel targeted treatment approaches. Using a case-based approach, faculty will illustrate the utilization of the updated classification scheme, including new terminology, relevant clinical findings, peripheral blood smear morphology, bone marrow aspirate smears and histology, and laboratory/molecular testing. Following this session, participants may complete a related online self-assessment module, available at cap.org through October 26, 2011.
You will learn to:
- Classify the myeloproliferative neoplasms using the WHO Classification
- Recommend specific molecular testing based on clinical, laboratory, and morphologic findings
- Interpret the results of molecular analysis of JAK2, MPL, KIT, ABL1, PDGFRA, PDGFRB, and FGFR1
- Recognize the treatment decision points of myeloproliferative neoplasms and the specific information you need to include in your pathology reports
- Describe how molecular testing can have implications for novel treatment approaches
Faculty
Joan E. Etzell, MD, FCAP
Jason R. Gotlib, MD, MS
Also offered as a virtual course—see Virtual Courses Tab for more details.